Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Thymulin (THLN) is a immune peptide, at the preclinical stage in the published literature. Nonapeptide hormone produced by thymic epithelial cells. Essential for T-cell maturation and differentiation.
Nonapeptide hormone produced by thymic epithelial cells. Essential for T-cell maturation and differentiation.
| Research Status | Preclinical |
|---|---|
| Half-Life | Unknown |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 1-10 mcg |
Zinc-dependent peptide that modulates T-cell development and immune function.
Nonapeptide hormone produced by thymic epithelial cells. Essential for T-cell maturation and differentiation.
Zinc-dependent peptide that modulates T-cell development and immune function.
Thymulin is at the following stage in the published literature: Preclinical. All information is for research and educational purposes only.
Reported half-life: Unknown.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.